Affiliation:
1. Department of Endocrinology (Austin Health), Heidelberg, University of Melbourne, Victoria, Australia
2. Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Abstract
Abstract
Context
Preclinical data has shown progesterone metabolites improve sleep parameters through positive allosteric modulation of the γ-aminobutyric acid type A receptor. We undertook a systematic review and meta-analysis of randomized controlled trials to assess micronized progesterone treatment on sleep outcomes.
Evidence Acquisition
Using preferred reporting items for systematic review and meta-analysis guidelines, we searched MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of micronized progesterone treatment on sleep outcomes up to March 31, 2020. This study is registered with the International Prospective Register of Systematic Reviews, number CRD42020165981. A random effects model was used for quantitative analysis.
Evidence Synthesis
Our search strategy retrieved 9 randomized controlled trials comprising 388 participants. One additional unpublished trial was found. Eight trials enrolled postmenopausal women. Compared with placebo, micronized progesterone improved various sleep parameters as measured by polysomnography, including total sleep time and sleep onset latency, though studies were inconsistent. Meta-analysis of 4 trials favored micronized progesterone for sleep onset latency (effect size, 7.10; confidence interval [CI] 1.30, 12.91) but not total sleep time (effect size, 20.72; CI -0.16, 41.59) or sleep efficiency (effect size, 1.31; CI -2.09, 4.70). Self-reported sleep outcomes improved in most trials. Concomitant estradiol administration and improvement in vasomotor symptoms limit conclusions in some studies.
Conclusions
Micronized progesterone improves various sleep outcomes in randomized controlled trials, predominantly in studies enrolling postmenopausal women. Further research could evaluate the efficacy of micronized progesterone monotherapy using polysomnography or validated questionnaires in larger cohorts.
Funder
Australian Government National Health and Medical Research Council Early Career Fellowship
Viertel Charitable Foundation Clinical Investigator Award
Endocrine Society of Australia Ken Wynne Award
Royal Australasian College of Physicians Foundation
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference35 articles.
1. Differential effects of progestins on the brain;Gruber;Maturitas.,2003
2. Allopregnanolone affects sleep in a benzodiazepine-like fashion;Lancel;J Pharmacol Exp Ther.,1997
3. The GABA(A) receptor antagonist picrotoxin attenuates most sleep changes induced by progesterone;Lancel;Psychopharmacology (Berl).,1999
4. Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators;Lancel;Am J Physiol.,1996
5. Prevalence and correlates of sleep disturbance in postmenopausal women: the Australian healthy aging of women (HOW) study;Seib;J Womens Health (Larchmt).,2014
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献